The FDA has denied IceCure Medical Ltd's ICCM De Novo Classification request for the ProSense System for breast cancer, which was submitted based on interim…
The FDA has denied IceCure Medical Ltd's (NASDAQ: ICCM) De Novo Classification request for the ProSense System for breast cancer, which was submitted based on interim
IceCure Medical s (ICCM) ProSense Cryoablation System Receives Regulatory Approval in Brazil streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.
Professor Eisuke Fukuma, who has performed over 600 ProSense breast cancer cryoablation procedures, led a cryoablation symposium with ProSenseIceCure joined its exclusive regional distributor,.
IceCure Medical Ltd. (Nasdaq: ICCM) ("IceCure" or the "Company"), developer of the ProSense® System, a minimally-invasive cryoablation technology that destroys tumors by freezing as an alternative to surgical tumor removal, today reported financial results as of and for the six months ended June 30, 2023, as well as operational and recent corporate developments.